Vident Investment Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Vident Investment Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,668	Closed	-$200K	–	925
2023 Q2	$200K	Buy	+6,668	New	+$233K	0.01%	1063
2022 Q3	–	Sell	-12,919	Closed	-$374K	–	1308
2022 Q2	$374K	Sell	12,919 -1,118	-8%	-$32K	0.01%	940
2022 Q1	$453K	Sell	14,037 -840	-6%	-$25.8K	0.01%	953
2021 Q4	$434K	Buy	14,877 +5,373	+57%	+$163K	0.01%	967
2021 Q3	$253K	Sell	9,504 -5,779	-38%	-$155K	0.01%	1036
2021 Q2	$471K	Buy	15,283 +5,351	+54%	+$164K	0.01%	858
2021 Q1	$260K	Sell	9,932 -621	-6%	-$17.4K	0.01%	930
2020 Q4	$266K	Sell	10,553 -295	-3%	-$6.35K	0.01%	835
2020 Q3	$226K	Buy	+10,848	New	+$246K	0.01%	815
2015 Q4	–	Sell	-52,952	Closed	-$743K	–	787
2015 Q3	$743K	Buy	+52,952	New	+$985K	0.1%	304

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vident Investment Advisory's SUPN Position: Q3 2023 in Review

Vident Investment Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 6,668 shares — an estimated $200K sold.

Vident Investment Advisory first reported a position in SUPN in Q3 2015 and held it in 10 quarters. The position peaked at $743K in Q3 2015. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

Vident Investment Advisory reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 6,668 Supernus Pharmaceuticals shares in Q3 2023, an estimated $200K.
Vident Investment Advisory first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 10 quarters.
Vident Investment Advisory's Supernus Pharmaceuticals position peaked at $743K in Q3 2015.
238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.